BRIMOGANCopy

• DRUGBANK - Brimonidine
• indication:

  For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

• pharmacology:

• mechanism:

  Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

• toxicity:

  Oral LD<sub>50</sub> is 50 mg/kg in mice and 100 mg/kg in rats.

• absorprion:

  Minimal systemic absorption occurs after ocular insertion.

• halflife:

  2 hours

• roouteelimination:

  It is metabolized primarily by the liver. Urinary excretion is the major route of elimination of the drug and its metabolites.

• volumedistribution:

• clearance: